Japan Sees Hottest September Since Records Began 

Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
TT

Japan Sees Hottest September Since Records Began 

Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)
Young women use portable fans to seek relief from the heat as temperatures soar in Japan. (AFP)

Japan has seen its hottest September since records began 125 years ago, the weather agency said, in a year expected to be the warmest in human history.

The scorching September's average temperature was 2.66 degrees Celsius higher than usual, the Japan Meteorological Agency said on Monday.

This was "the highest figure since the start of statistics in 1898", the agency said in a statement.

This year is expected to be the hottest in human history as climate change accelerates, with countries including Austria, France, Germany, Poland and Switzerland each announcing their warmest September on record.

Across Japan last month, 100 of 153 observation locations broke an average temperature record, including in Tokyo, with an all-time high of 26.7 degrees Celsius (80 degrees Fahrenheit), in Osaka with 27.9C and in Nagoya with 27.3C.

The average temperature jump of 2.66C was "extraordinary" and "easily topped previous highs", weather agency official Masayuki Hirai told AFP on Tuesday.

"If this is not an abnormally high temperature, I don't know what is," he said.

French weather authority Meteo-France said the September temperature average in the country will be around 21.5 degrees Celsius, between 3.5C and 3.6C above the 1991-2020 reference period.

The UK, too, has matched its record for the warmest September since records began in 1884.

The average global temperature in June, July and August was 16.77 degrees Celsius, surpassing the previous 2019 record, the European Union's Copernicus Climate Change Service (C3S) said in a report.

In September, UN Secretary-General Antonio Guterres told world leaders the climate crisis had "opened the gates to hell".

In his opening address at the Climate Ambition Summit, Guterres evoked this year's "horrendous heat" but stressed: "We can still limit the rise in global temperature to 1.5 degrees," referring to the target seen as needed to avoid long-term climate catastrophe.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”